MedTrace Logo

Investigation of Serious Adverse Events Following Vaccination Against Yellow Fever: Emphasis on Genetic Basis and Biological Markers

NCT03938597 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2023-06-15

No results posted yet for this study

Summary

It concerns an investigation aiming to investigate genetic biological(s) marker(s) which allow to identify individuals who have risk of serious adverse events to the yellow fever vaccine. This testing is free of hypothesis, because these markers are still unknown. There is no intervention, and it is not possible to establish primary and secondary outcomes.

Conditions

  • Drug-Related Side Effects and Adverse Reactions

Sponsors & Collaborators

  • Rockefeller University

    collaborator OTHER

  • The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)

    lead OTHER

Eligibility

Min Age
9 Months
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-30
Primary Completion
2023-06-30
Completion
2023-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03938597 on ClinicalTrials.gov